

Deals,
from previous page

CuraGen Corp. (CRGN), Branford, Conn.

Broad Institute, Cambridge, Mass.

Business: Genomics

The institute will use the Genome Sequencer 20 System from CRGN subsidiary 454 Life Sciences to research the genetic basis for cancer, diabetes and heart disease.

CytRx Corp. (CYTR), Los Angeles, Calif.

University of Massachusetts Medical School, Worcester, Mass.

Business: Metabolic

The university granted CYTR rights to targets that regulate insulin activity in fat cells. CYTR plans to develop small molecules that modulate the targets. Further terms were not disclosed.

Discovery Laboratories Inc. (DSCO), Warrington, Penn.

Safeguard Scientifics Inc. (SFE), Wayne, Penn.

Business: Manufacturing

DSCO will purchase the Totowa, N.J., manufacturing operations of SFE's Laureate Pharma Inc. subsidiary (Princeton, N.J.) for \$16 million in cash. The facility has been producing DSCO's Surfaxin humanized lung surfactant to prevent Respiratory Distress Syndrome (RDS) in premature infants. DSCO hopes to launch Surfaxin in the second quarter.

Dyax Corp. (DYAX), Cambridge, Mass.

Debiopharm S.A., Lausanne, Switzerland

Business: Pulmonary

The companies restructured a 2001 deal to develop Depelestat, an EPI-HNE-4 human neutrophil elastase inhibitor that was discovered by DYAX and developed by Debiopharm (see *BioCentury*, Jan. 29, 2001). Debiopharm now will have exclusive worldwide rights to develop, manufacture and commercialize a native form of Depelestat to treat cystic fibrosis (CF) and acute respiratory distress syndrome (ARDS). DYAX will be eligible for milestones and royalties, and retains exclusive worldwide rights to develop, manufacture and commercialize versions of Depelestat with improved half-lives to treat other chronic pulmonary indications.

EntreMed Inc. (ENMD), Rockville, Md.

Miikana Therapeutics Inc., Fremont, Calif.

Business: Cancer

Cancer and inflammation company ENMD will acquire Miikana for 10 million shares, which values Miikana at \$21.2 million using ENMD's close of \$2.13 on Dec. 21, the day before the deal was announced. Miikana shareholders are eligible for up to \$18 million in milestones, payable in cash or stock at ENMD's option. The deal is expected to close this month.

Miikana's compounds include MKC-1, an oral small molecule cell cycle inhibitor that is expected to start Phase II testing early this year to treat metastatic breast cancer; MKC-1693, an aurora kinase inhibitor that is in preclinical development for cancer; and MKC-1704, a histone deacetylase (HDAC) inhibitor that is in preclinical testing for cancer.

Esprit Pharma Inc., East Brunswick, N.J.

Novavax Inc. (NVAX), Malvern, Penn.

Business: Metabolic, Drug delivery

NVAX received an \$8 million license payment from Esprit, which brings to \$10 million the amount NVAX has received since granting Esprit exclusive North American marketing rights to Estrasorb topical 17beta estradiol emulsion to reduce moderate to severe vasomotor symptoms in menopausal women (see *BioCentury*, Oct. 24, 2005). NVAX

will receive an additional \$2.5 million in October and is eligible for sales milestones and royalties.

Exelixis Inc. (EXEL), South San Francisco, Calif.

Washington State University, Pullman, Wash.

Business: Biomanufacturing

The university's tech transfer arm, Washington State University Research Foundation, granted EXEL's Exelixis Plant Sciences Inc. subsidiary (Portland, Ore.) a license to IP and materials used to produce paclitaxel and other taxanes in plant cell culture. Further terms were not disclosed.

Exelixis Inc. (EXEL), South San Francisco, Calif.

Wyeth (WYE), Madison, N.J.

Business: Metabolic

EXEL granted WYE a license to preclinical compounds targeting the farnesoid X receptor (FXR) for metabolic and liver disorders. WYE is responsible for development, regulatory submissions, manufacturing and commercialization. EXEL will receive \$10 million up front and is eligible for up to \$147.5 million in milestones, plus royalties. EXEL gained rights to FXR, a nuclear hormone receptor, through its 2004 acquisition of X-Ceptor (see *BioCentury*, Oct. 4, 2004).

Genedata AG, Basel, Switzerland

Roche (SWX:ROCZ), Basel, Switzerland

Business: High throughput screening

The companies expanded their high throughput screening deal to include all ROCZ screening facilities in North America and Europe. ROCZ is using Genedata's Genedata Screener for lead discovery.

Genentech Inc. (DNA), South San Francisco, Calif.

Lexicon Genetics Inc. (LEXG), The Woodlands, Texas

Business: Functional genomics

LEXG earned two milestone payments totaling \$20 million from DNA. The first payment was triggered by completing the analysis of the final set of targets selected from DNA's Secreted Protein Discovery Initiative (SPDI) program under a 2002 deal. The second milestone was related to an expansion of that deal and was triggered by LEXG delivering data from research to further elucidate the functions of potential therapeutic proteins and antibody targets identified in the partners' initial collaboration.

GenVec Inc. (GNVC), Gaithersburg, Md.

Mytogen Inc., Charlestown, Mass.

Business: Gene/Cell therapy

GNVC completed the previously announced sale of its myoblast cell therapy program for heart failure to Mytogen (see *BioCentury*, Oct. 24, 2005). GNVC is eligible for milestones and royalties.

GPC Biotech AG (FSE:GPC; GPCB), Munich, Germany

Pharmion Corp. (PHRM), Boulder, Colo.

Spectrum Pharmaceuticals Inc. (SPPI), Irvine, Calif.

Business: Cancer

GPC granted PHRM exclusive rights to commercialize satraplatin in Europe, Turkey, the Middle East, Australia and New Zealand. GPC retains rights elsewhere. The oral platinum compound is in Phase III testing to treat second-line hormone-refractory prostate cancer (HRPC). GPC expects to submit an MAA for second-line HRPC in 2007.

PHRM will pay GPC \$59.3 million for development costs, including \$37.1 million up front. GPC is eligible for \$210.5 million in milestones, including \$30.5 million in regulatory milestones, \$75 million for up to five EMEA approvals in additional indications and \$105 million in sales

See next page